<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00004827</url>
  </required_header>
  <id_info>
    <org_study_id>199/13351</org_study_id>
    <secondary_id>RFS-FDR001232</secondary_id>
    <nct_id>NCT00004827</nct_id>
  </id_info>
  <brief_title>Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Foundation of the Southwest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>FDA Office of Orphan Products Development</source>
  <brief_summary>
    <textblock>
      OBJECTIVES:

      I. Evaluate the potential of nutritional docosahexaenoic acid (DHA) supplementation to
      normalize the level of DHA in red blood cells, and to retard the progression of visual
      function loss in patients with early stage X-linked retinitis pigmentosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PROTOCOL OUTLINE: This is a randomized, parallel, double blind study. Patients receive 2 gel
      capsules per day of either docosahexaenoic acid (DHA) enriched oil or a placebo oil. Oral DHA
      supplementation continues daily for 3 years.

      All patients are followed every 6 months for the 3 year duration of the study.

      Completion date provided represents the completion date of the grant per OOPD records
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 1996</start_date>
  <completion_date>June 2002</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <enrollment>46</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docosahexaenoic acid</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        PROTOCOL ENTRY CRITERIA:

        --Disease Characteristics--

        Diagnosis of X-linked retinitis pigmentosa

        Early stage disease Sufficient cone function determined by recordable ERG (30 Hz amplitude;
        greater than 0.32 microvolts) Visual fields greater than 20 degrees Sufficient rod function
        (greater than 3.0 microvolts amplitude)

        Media clarity sufficient for fundus photography

        --Prior/Concurrent Therapy--

        No concurrent use of anticoagulant medication

        --Patient Characteristics--

          -  No chronic metabolic disease that may interfere with fatty acid metabolism

          -  No bleeding of clinical significance
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis R. Hoffman</last_name>
    <role>Study Chair</role>
    <affiliation>Retina Foundation of the Southwest</affiliation>
  </overall_official>
  <verification_date>May 1998</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 24, 2000</study_first_submitted>
  <study_first_submitted_qc>February 24, 2000</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2000</study_first_posted>
  <last_update_submitted>March 24, 2015</last_update_submitted>
  <last_update_submitted_qc>March 24, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 25, 2015</last_update_posted>
  <keyword>ophthalmologic disorders</keyword>
  <keyword>rare disease</keyword>
  <keyword>retinitis pigmentosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Cone-Rod Dystrophies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

